311 related articles for article (PubMed ID: 4035777)
1. Dapsone resistant leprosy, the western Kenya experience.
Orege PA; Owili DM
Trop Geogr Med; 1985 Jun; 37(2):139-42. PubMed ID: 4035777
[TBL] [Abstract][Full Text] [Related]
2. Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai control units of Tamil Nadu.
Neelan PN; Noordeen SK; Balakrishnan S; Pandian PR
Lepr India; 1983 Apr; 55(2):222-30. PubMed ID: 6355650
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary report.
Balraj V; Jesudasan K; Chacko CJ; Christian M; Taylor PM; Fritschi EP; Job CK
Int J Lepr Other Mycobact Dis; 1980 Dec; 48(4):397-401. PubMed ID: 7193654
[TBL] [Abstract][Full Text] [Related]
4. Infectivity of secondary dapsone-resistant cases.
Jesudasan K; Pannikar V; Christian M
Int J Lepr Other Mycobact Dis; 1988 Sep; 56(3):418-21. PubMed ID: 3047282
[TBL] [Abstract][Full Text] [Related]
5. DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results.
Almeida JG; Chacko CJ; Christian M; Taylor PM; Fritschi EP
Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):366-73. PubMed ID: 6685699
[TBL] [Abstract][Full Text] [Related]
6. [2 cases of paucibacillary leprosy resistant to dapsone].
Janssens L
Acta Leprol; 1982; (86-87):181-3. PubMed ID: 6815986
[TBL] [Abstract][Full Text] [Related]
7. Response to dapsone (DDS) monotherapy in leprosy patients of Gudiyatham Taluk, South India: comparison between the 1960s and the 1970s.
Almeida JG; Christian M; Chacko CJ
Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):378-8. PubMed ID: 6685701
[TBL] [Abstract][Full Text] [Related]
8. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of drug resistance in Dharmapuri and A. Pallipatti areas of Tamil Nadu.
Sreevatsa ; Ramu G; Desikan KV
Indian J Lepr; 1985; 57(2):376-82. PubMed ID: 3908580
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India.
Almeida JG; Christian M; Chacko CJ
Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):382-4. PubMed ID: 6685702
[TBL] [Abstract][Full Text] [Related]
11. Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment.
Warndorff van Diepen T; Mengistu G
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):189-97. PubMed ID: 2410520
[TBL] [Abstract][Full Text] [Related]
12. Secondary and primary dapsone resistant leprosy: an analysis of 199 patients from St. Thomas Hospital and leprosy project, Chettupattu, South India.
Aschhoff M; Raj PP; Lilly L; Srinivasan H
Indian J Lepr; 1988 Jan; 60(1):34-46. PubMed ID: 3060545
[TBL] [Abstract][Full Text] [Related]
13. Multiple relapses in borderline leprosy--a case report.
Ramachandran A; Seshadri PS
Indian J Lepr; 1986; 58(4):623-5. PubMed ID: 3553362
[TBL] [Abstract][Full Text] [Related]
14. Primary dapsone-resistant leprosy in Cebu, Philippines.
Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC
Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
[TBL] [Abstract][Full Text] [Related]
16. Primary dapsone-resistant leprosy in San Francisco.
Gelber RH
Int J Lepr Other Mycobact Dis; 1984 Dec; 52(4):471-4. PubMed ID: 6399067
[TBL] [Abstract][Full Text] [Related]
17. The clinical diagnosis of dapsone resistant leprosy.
Taylor PM
Lepr India; 1982 Jan; 54(1):117-22. PubMed ID: 7047897
[TBL] [Abstract][Full Text] [Related]
18. Ocular complications in incident relapsed borderline lepromatous and lepromatous leprosy patients in south India.
Daniel E; Koshy S; Joseph GA; Rao PS
Indian J Ophthalmol; 2003 Jun; 51(2):155-9. PubMed ID: 12831146
[TBL] [Abstract][Full Text] [Related]
19. Lepromatous leprosy: dapsone resistance.
Barrett DF
Proc R Soc Med; 1976 Jun; 69(6):391-2. PubMed ID: 959208
[No Abstract] [Full Text] [Related]
20. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
Chandorkar AG; Burte NP; Gade RK; Bulakh PM
Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
